Literature DB >> 22477037

Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.

José A Pérez-Molina1, Francesca Norman, Rogelio López-Vélez.   

Abstract

Imported Chagas disease (Trypanosoma cruzi infection) is increasingly recognized as an emerging problem in the USA and Europe due to immigration from Latin America. Most migrants from endemic countries will have been infected during childhood. Based on the natural history of the disease, up to 35 % of those infected may develop cardiac and/or gastrointestinal manifestations during the third or fourth decade of life. This disease was described more than 100 years ago, yet many challenges still remain such as the identification of risk factors for visceral involvement, effective treatment for chronic cases, and reliable markers of cure following treatment. Transmission of the infection may occur even in non-endemic areas through non-vectorial routes and many countries are therefore currently facing the challenge of this emerging public health problem.

Entities:  

Year:  2012        PMID: 22477037     DOI: 10.1007/s11908-012-0259-3

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  95 in total

1.  [Treatment of chronic Chagas' disease with an association of nifurtimox and corticoid].

Authors:  Anis Rassi; Vicente Amato Neto; Astolpho Ferraz de Siqueira; Francisco Ferriolli Filho; Valdir Sabbaga Amato; Gustavo Gabriel Rassi; Anis Rassi Junior
Journal:  Rev Soc Bras Med Trop       Date:  2003-02-26       Impact factor: 1.581

2.  Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).

Authors:  Jose Antonio Marin-Neto; Anis Rassi; Carlos A Morillo; Alvaro Avezum; Stuart J Connolly; Sergio Sosa-Estani; Fernando Rosas; Salim Yusuf
Journal:  Am Heart J       Date:  2008-07       Impact factor: 4.749

3.  [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].

Authors:  J R Coura; L L de Abreu; H P Willcox; W Petana
Journal:  Rev Soc Bras Med Trop       Date:  1997 Mar-Apr       Impact factor: 1.581

4.  Usefulness of qualitative polymerase chain reaction for Trypanosoma cruzi DNA in endomyocardial biopsy specimens of chagasic heart transplant patients.

Authors:  Luiz A Benvenuti; Alessandra Roggério; Guilherme Coelho; Alfredo I Fiorelli
Journal:  J Heart Lung Transplant       Date:  2011-04-09       Impact factor: 10.247

5.  The effect of nifurtimox in acute Chagas' infection.

Authors:  D H Wegner; R W Rohwedder
Journal:  Arzneimittelforschung       Date:  1972-09

Review 6.  Chagas disease and stroke.

Authors:  Francisco Javier Carod-Artal; Joaquim Gascon
Journal:  Lancet Neurol       Date:  2010-05       Impact factor: 44.182

Review 7.  Congenital transmission of Chagas disease: a clinical approach.

Authors:  Inés Oliveira; Faustino Torrico; Jose Muñoz; Joaquim Gascon
Journal:  Expert Rev Anti Infect Ther       Date:  2010-08       Impact factor: 5.091

8.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

9.  Administration of benznidazole, a chemotherapeutic agent against Chagas disease, to pregnant rats. Covalent binding of reactive metabolites to fetal and maternal proteins.

Authors:  E G de Toranzo; M Masana; J A Castro
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-11

Review 10.  Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis.

Authors:  José A Pérez-Molina; Ana Pérez-Ayala; Santiago Moreno; M Carmen Fernández-González; Javier Zamora; Rogelio López-Velez
Journal:  J Antimicrob Chemother       Date:  2009-10-09       Impact factor: 5.790

View more
  28 in total

1.  Involvement of sulfates from cruzipain, a major antigen of Trypanosoma cruzi, in the interaction with immunomodulatory molecule Siglec-E.

Authors:  Maximiliano R Ferrero; Anja M Heins; Luciana L Soprano; Diana M Acosta; Mónica I Esteva; Thomas Jacobs; Vilma G Duschak
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

2.  Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy.

Authors:  Chiara Di Girolamo; Giulia Martelli; Anna Ciannameo; Caterina Vocale; Marco Fini; Angelo Stefanini; Maria Paola Landini; Pierluigi Viale; Gabriella Verucchi
Journal:  J Immigr Minor Health       Date:  2016-06

3.  Trypanosoma cruzi serinecarboxipeptidase is a sulfated glycoprotein and a minor antigen in human Chagas disease infection.

Authors:  Luciana L Soprano; Juliana E Parente; Malena Landoni; Alicia S Couto; Vilma G Duschak
Journal:  Med Microbiol Immunol       Date:  2017-12-22       Impact factor: 3.402

4.  A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.

Authors:  Gilberto Marcelo Sperandio da Silva; Mauro Felippe Felix Mediano; Pedro Emmanuel Alvarenga Americano do Brasil; Mayara da Costa Chambela; Joyce Almeida da Silva; Andrea Silvestre de Sousa; Sergio Salles Xavier; Andrea Rodrigues da Costa; Roberto Magalhães Saraiva; Alejandro Marcel Hasslocher-Moreno
Journal:  Antimicrob Agents Chemother       Date:  2014-08-11       Impact factor: 5.191

5.  Nitrotriazole-Based Compounds as Antichagasic Agents in a Long-Treatment In Vivo Assay.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Ana Lia Mazzeti; Karolina Ribeiro Gonçalves; Priscila Fagundes Mendes; Maria Terezinha Bahia
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

6.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

7.  Dried blood as an alternative to plasma or serum for Trypanosoma cruzi IgG detection in screening programs.

Authors:  Africa Holguín; Francesca Norman; Leticia Martín; María Luisa Mateos; Jesús Chacón; Rogelio López-Vélez; José A Pérez-Molina
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

8.  Inhibition of cyclooxygenase-1 and cyclooxygenase-2 impairs Trypanosoma cruzi entry into cardiac cells and promotes differential modulation of the inflammatory response.

Authors:  Aparecida D Malvezi; Carolina Panis; Rosiane V da Silva; Rafael Carvalho de Freitas; Maria I Lovo-Martins; Vera L H Tatakihara; Nágela G Zanluqui; Edecio Cunha Neto; Samuel Goldenberg; Juliano Bordignon; Sueli F Yamada-Ogatta; Marli C Martins-Pinge; Rubens Cecchini; Phileno Pinge-Filho
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Trypanosoma cruzi seroprevalence and associated factors in women in Casanare-Colombia.

Authors:  Angela Liliana Monroy Díaz; Fabiana Pregonero Sigua; Aura Shirley Otálora; Adriana Maria Pedraza Bernal
Journal:  J Parasit Dis       Date:  2020-10-01

10.  Insights of antiparasitic activity of sodium diethyldithiocarbamate against different strains of Trypanosoma cruzi.

Authors:  Johny Wysllas de Freitas Oliveira; Taffarel Melo Torres; Cláudia Jassica Gonçalves Moreno; Bruno Amorim-Carmo; Igor Zumba Damasceno; Ana Katarina Menezes Cruz Soares; Jefferson da Silva Barbosa; Hugo Alexandre Oliveira Rocha; Marcelo Sousa Silva
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.